Back to results
US 10,086,066 B2Granted
Tissue targeted antigenic activation of the immune response to treat cancers
AssigneeQu Biologics Inc.
InventorHarold David Gunn
Life of this patent
Estimating the term…
Abstract
The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.
Claims14
A method for treating a human patient for a cancer situated in a lung tissue, the method consisting essentially of:
- administering to the patient a medicament consisting essentially of an effective amount of an antigenic composition consisting essentially of whole killed or attenuated cells of one microbial pathogen, wherein the microbial pathogen is Klebsiella pneumoniae;
- wherein the medicament is administered to the patient in an amount and for a time that is effective to treat the cancer, and the administration site is distant from the lung and microbial antigenic determinants of Klebsiella pneumoniae are the sole antigens for treating the cancer.
A method for treating a human patient for a cancer situated in a lung tissue, the method comprising:
- intradermally or subcutaneously administering to the patient a medicament comprising an effective amount of an antigenic composition comprising whole killed cells of only one microbial pathogen, so that the cells of the microbial pathogen do not produce an infection at the cancer site, wherein the microbial pathogen is Klebsiella pneumoniae;
- administering the medicament in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks in an amount and for a time that is effective for treating a human patient for a cancer situated in a lung tissue, and the administration site is distant from the lung.
A method for treating a human patient for a cancer situated in a lung tissue, the method comprising:
- administering to the patient a medicament comprising an effective amount of an antigenic composition comprising whole killed cells of only one microbial pathogen, wherein the microbial pathogen is Klebsiella pneumoniae,
- wherein microbial antigenic determinants of Klebsiella pneumoniae are the sole antigens for treating the cancer.
Dependencies are inferred from the claim text.